SG80090G - (s)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide - Google Patents

(s)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide

Info

Publication number
SG80090G
SG80090G SG800/90A SG80090A SG80090G SG 80090 G SG80090 G SG 80090G SG 800/90 A SG800/90 A SG 800/90A SG 80090 A SG80090 A SG 80090A SG 80090 G SG80090 G SG 80090G
Authority
SG
Singapore
Prior art keywords
radical
oxo
alpha
ethyl
pyrrolidinacetamide
Prior art date
Application number
SG800/90A
Other languages
English (en)
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10560974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG80090(G) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of SG80090G publication Critical patent/SG80090G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG800/90A 1984-05-15 1990-10-02 (s)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide SG80090G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848412357A GB8412357D0 (en) 1984-05-15 1984-05-15 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
SG80090G true SG80090G (en) 1990-11-23

Family

ID=10560974

Family Applications (1)

Application Number Title Priority Date Filing Date
SG800/90A SG80090G (en) 1984-05-15 1990-10-02 (s)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide

Country Status (33)

Country Link
US (3) US4696943A (de)
EP (1) EP0162036B1 (de)
JP (1) JPH0629186B2 (de)
KR (1) KR920003819B1 (de)
CN (1) CN1015541B (de)
AT (1) ATE45567T1 (de)
AU (1) AU574465B2 (de)
BG (2) BG50156A3 (de)
CA (1) CA1235129A (de)
CY (2) CY1567A (de)
DE (3) DE10075021I1 (de)
DK (1) DK163501C (de)
ES (2) ES8608485A1 (de)
FI (1) FI80673C (de)
GB (1) GB8412357D0 (de)
GE (1) GEP20002001B (de)
GR (1) GR851155B (de)
HK (1) HK52391A (de)
IE (1) IE59950B1 (de)
IL (1) IL75179A (de)
LT (1) LT2584B (de)
LU (2) LU90615I2 (de)
LV (1) LV5233A3 (de)
MY (2) MY101725A (de)
NL (1) NL300028I2 (de)
NO (2) NO164534C (de)
PL (2) PL144346B1 (de)
PT (1) PT80460B (de)
SA (1) SA01210656A (de)
SG (1) SG80090G (de)
SU (3) SU1402260A3 (de)
UA (1) UA6158A1 (de)
ZA (1) ZA853635B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827389D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US6107492A (en) * 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
US6124473A (en) * 1998-05-08 2000-09-26 Ucb, S.A. Process for preparing (s)- and (R)-α-ethyl-2-oxo-1-pyrrolidineacetamide
EA002379B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Средство, обладающее антиишемической, гипотензивной и антигипоксической активностью
EA002380B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Антиишемическое средство
NZ518901A (en) 1999-12-01 2004-08-27 Ucb S A levetiracetam alone or in combination with a compound inducing neural inhibition mediated by the GABA receptors for treatment of chronic pain, bipolar disorder, mania and migraine
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
JPWO2002053153A1 (ja) * 2000-12-28 2004-04-30 第一製薬株式会社 神経因性疼痛治療及び予防薬
AU2002245486B2 (en) * 2001-02-23 2006-11-16 Ucb Pharma, S.A. Treatment of tics, tremors and related disorders
JP4334344B2 (ja) * 2001-08-10 2009-09-30 ユセベ ファルマ ソシエテ アノニム オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用
US20040242671A1 (en) * 2001-10-08 2004-12-02 Renee Grimee Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
WO2003094913A1 (en) * 2002-05-14 2003-11-20 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
EP1517893A2 (de) * 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Verfahren zur herstellung von levetiracetam
ES2214147B1 (es) * 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
TR200503397T1 (tr) * 2003-03-18 2007-03-21 Hetero Drugs Limited Levetirasetam'ın yeni kristal formları.
EP1663968A1 (de) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Verfahren zur herstellung von reinem levetiracetam
CA2538938C (en) * 2003-09-24 2011-08-09 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives
BRPI0417157A (pt) 2003-12-02 2007-03-06 Ucb Sa composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CA2497062A1 (en) 2004-02-18 2005-08-18 Dr. Reddy's Laboratories Limited Preparation of amino acid amides
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
WO2006080029A1 (en) * 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006090265A2 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
US20080146819A1 (en) * 2005-03-10 2008-06-19 Rubamin Limited Process for Preparing Levetiracetam
EP1871363A4 (de) * 2005-03-30 2009-01-21 Genpharm Inc Kombinierter stufenprozess für pharmazeutische zusammensetzungen
EP1879861A2 (de) * 2005-04-01 2008-01-23 Rubamin Laboratories Limited Verfahren zur herstellung von levetiracetam und racemisierung von (r)- und (s)-2-aminobuttersäureamid und den entsprechenden säurederivaten
US8178533B2 (en) 2005-06-01 2012-05-15 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
PE20070216A1 (es) * 2005-07-26 2007-03-27 Ucb Sa Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
US20070172521A1 (en) * 2006-01-24 2007-07-26 Julia Hrakovsky Levetiracetam formulations and methods for their manufacture
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008012268A1 (en) * 2006-07-25 2008-01-31 Zach System S.P.A. Process for the preparation of levetiracetam
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
CN101130504B (zh) * 2006-08-25 2010-07-28 苏州雅本化学股份有限公司 经合成、拆分与消旋化制备手性药物左乙拉西坦中间体(s)-(+)-2-氨基丁酰胺盐酸盐的方法
EP1932922A1 (de) * 2006-12-13 2008-06-18 Desitin Arzneimittel GmbH Schnelltest zum Nachweis von DNA-Sequenzen
WO2008077035A2 (en) * 2006-12-18 2008-06-26 Dr. Reddy's Laboratories Ltd. Processes for the preparation of levetiracetam
CN101333180B (zh) * 2007-06-29 2011-05-18 浙江华海药业股份有限公司 一种制备左乙拉西坦中间体的方法
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
WO2009050735A1 (en) * 2007-10-15 2009-04-23 Lupin Limited A novel polymorph of levetiracetam and a process for its preparation
US20090263481A1 (en) * 2008-04-17 2009-10-22 Atul Vishvanath Patil Levetiracetam formulations
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
EP2147911A1 (de) 2008-07-24 2010-01-27 ZaCh System S.p.A. Verfahren zur Herstellung von Levetiracetam
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2009303834B2 (en) 2008-10-16 2016-08-11 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2179725A1 (de) 2008-10-23 2010-04-28 LEK Pharmaceuticals D.D. Pharmazeutische Zusammensetzung mit Levetiracetan
EP2341777B1 (de) * 2008-11-07 2015-01-21 NovaBay Pharmaceuticals, Inc. Antimikrobielle oxazolidinon-, hydantoin- und imidazolidinon-zusammensetzungen
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
CN101885696A (zh) * 2009-05-14 2010-11-17 上海华理生物医药有限公司 一种合成高纯度左乙拉西坦的方法
WO2011015349A2 (en) 2009-08-07 2011-02-10 Ucb Pharma, S.A. Methods for enhancing the cognitive function
EP2298290A1 (de) 2009-09-16 2011-03-23 LEK Pharmaceuticals d.d. Zusammensetzung mit Levetiracetam zur gesteuerten Abgabe
US7939676B2 (en) * 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
WO2011047860A1 (en) 2009-10-23 2011-04-28 Ucb Pharma, S.A. 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
EP2539444A4 (de) 2010-02-26 2013-09-18 Univ California Zusammensetzungen und verfahren zur herstellung von l-homoalanin
EP2563340A2 (de) 2010-04-26 2013-03-06 Mahmut Bilgic Wasserlösliche pharmazeutische zusammensetzung
US9333175B2 (en) 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
EP2492354A1 (de) 2011-02-23 2012-08-29 Institut National De La Recherche Agronomique (INRA) Verfahren zur Identifizierung von Verbindungen zur Behandlung lichtempfindlicher Reflexepilepsie
CA2831830C (en) 2011-04-18 2017-12-12 Ucb Pharma, S.A. 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
EP2524910A1 (en) 2011-05-17 2012-11-21 DSM IP Assets B.V. Process for the resolution of aminobutyramide
CN102382027B (zh) * 2011-09-20 2013-11-13 浙江江北药业有限公司 一种左乙拉西坦的制备方法
CN102617436B (zh) * 2012-03-20 2014-02-12 浙江洪波化工有限公司 2-(2-氧代吡咯烷基）丁酰胺的制备方法
CN102633675A (zh) * 2012-04-10 2012-08-15 南京大学 一种dl-2-氨基丁酰胺制备方法
CN102675181B (zh) * 2012-06-07 2013-11-20 北京师宏药物研制中心 一种左乙拉西坦的制备方法
CN102702063B (zh) * 2012-06-15 2013-09-04 孙威 一种左乙拉西坦制备方法
WO2014012563A1 (en) 2012-07-20 2014-01-23 Ucb Pharma, S.A. Compounds for enhancing the cognitive function
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103012190B (zh) * 2012-12-05 2015-03-18 江苏拜克新材料有限公司 一种s-2-氨基丁酰胺盐酸盐的合成方法
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CN105188849B (zh) 2013-03-15 2019-01-15 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散剂型
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN103922988A (zh) * 2014-04-29 2014-07-16 苏州天马精细化学品股份有限公司 一种左乙拉西坦粗品的纯化方法
CN103910649A (zh) * 2014-04-29 2014-07-09 苏州天马精细化学品股份有限公司 一种左乙拉西坦中间体（s）-n-[1-(氨基羰基)丙基]-4-氯代丁酰胺的合成方法
CN104860863B (zh) * 2015-04-10 2017-06-20 惠州信立泰药业有限公司 左乙拉西坦和含其的药物组合物
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
CN106432032B (zh) * 2016-09-14 2019-07-12 苏州天马药业有限公司 一种左乙拉西坦的制备方法
CN106591179B (zh) * 2016-12-05 2018-07-03 长兴制药股份有限公司 甲基包囊菌及其在选择性拆分制备(S)-α-乙基-2-氧-1-吡咯烷乙酸盐上的应用
BR112019011208A2 (pt) 2016-12-16 2019-10-15 Idorsia Pharmaceuticals Ltd combinação farmacêutica, composição farmacêutica, e, kit de partes.
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN107337628B (zh) * 2017-08-10 2022-02-08 浙江华海药业股份有限公司 一种制备左乙拉西坦的方法
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
CN110003074A (zh) 2019-04-23 2019-07-12 浙江华海药业股份有限公司 一种左乙拉西坦中间体的制备方法
TW202114655A (zh) 2019-08-14 2021-04-16 瑞士商辛鐵堤卡公司 左乙拉西坦(levetiracetam)之鞘內投藥
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
IL305471A (en) 2021-02-26 2023-10-01 Syndesi Therapeutics Sa Compounds for the treatment of cognitive disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1583871A (en) * 1976-10-19 1981-02-04 Ucb Sa Anti-aggregants
FR2418790A1 (fr) * 1978-03-02 1979-09-28 Philagro Sa Nouveaux derives de pyrrolidinone-2 et compositions herbicides les contenant
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition

Also Published As

Publication number Publication date
CY2004007I1 (el) 2009-11-04
PL144346B1 (en) 1988-05-31
NO164534B (no) 1990-07-09
ATE45567T1 (de) 1989-09-15
ES8608485A1 (es) 1986-06-16
DE10199005I2 (de) 2002-03-14
BG47497A3 (en) 1990-07-16
IE851193L (en) 1985-11-15
AU4253085A (en) 1986-11-20
ZA853635B (en) 1985-12-24
KR850008336A (ko) 1985-12-16
GEP20002001B (en) 2000-03-10
GR851155B (de) 1985-11-25
FI851875A0 (fi) 1985-05-13
US4943639A (en) 1990-07-24
SU1428195A3 (ru) 1988-09-30
IE59950B1 (en) 1994-05-04
LU90615I2 (fr) 2000-10-02
IL75179A0 (en) 1985-09-29
DK212985D0 (da) 1985-05-14
GB8412357D0 (en) 1984-06-20
US4696943A (en) 1987-09-29
PL253374A1 (en) 1986-05-06
ES8704893B9 (es) 2012-02-07
FI851875L (fi) 1985-11-16
DE10075021I1 (de) 2000-10-19
DE3572348D1 (de) 1989-09-21
US4837223A (en) 1989-06-06
CN85105301A (zh) 1987-01-14
DK163501C (da) 1992-07-27
HK52391A (en) 1991-07-19
CY2004007I2 (el) 2009-11-04
DK212985A (da) 1985-11-16
EP0162036A1 (de) 1985-11-21
ES8704893A1 (es) 1987-04-16
IL75179A (en) 1988-05-31
JPH0629186B2 (ja) 1994-04-20
PL257385A1 (en) 1986-10-07
MY101725A (en) 1992-01-17
NL300028I2 (nl) 2001-06-01
PL147386B1 (en) 1989-05-31
SU1430392A1 (ru) 1988-10-15
PT80460A (fr) 1985-06-01
PT80460B (pt) 1987-08-19
EP0162036B1 (de) 1989-08-16
SU1402260A3 (ru) 1988-06-07
FI80673B (fi) 1990-03-30
DE10199005I1 (de) 2001-07-12
NO851933L (no) 1985-11-18
CA1235129A (en) 1988-04-12
NL300028I1 (nl) 2001-02-01
CY1567A (en) 1991-12-20
KR920003819B1 (ko) 1992-05-15
JPS60252461A (ja) 1985-12-13
LT2584B (lt) 1994-03-25
DK163501B (da) 1992-03-09
LV5233A3 (lv) 1993-10-10
ES543124A0 (es) 1986-06-16
AU574465B2 (en) 1988-07-07
BG50156A3 (en) 1992-05-15
SA01210656A (ar) 2005-12-03
NO164534C (no) 1990-10-17
FI80673C (fi) 1990-07-10
MY101726A (en) 1992-01-17
LU90682I2 (fr) 2001-01-30
UA6158A1 (uk) 1994-12-29
NO2001008I2 (no) 2005-05-30
CN1015541B (zh) 1992-02-19

Similar Documents

Publication Publication Date Title
AU574465B2 (en) (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
AU574175B2 (en) (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide